Lantheus Holdings

Organisation

201 Burlington Road, Bedford, MA, United States, 01730

Headquarters

1193

Employees

Health Technology

Industry

Mary Heino

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. It also provides Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; PYLARIFY AI, an medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer; and flurpiridaz used to assess blood flow to the heart. In addition, it develops PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy to patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent for Tau tangles in Alzheimer's disease; LNTH-2401, a novel radiodiagnostic targeting the gastrin-releasing peptide receptor; LNTH-2402; LNTH-2403; LNTH-2404; LNTH-250; LNTH-2515; and LNTH-1363S, an fibroblast activation protein, alpha, copper-64 labeled PET imaging agent. It has collaboration agreements with GE Healthcare; Curium Pharma; POINT; Regeneron; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Price

Target

Lantheus Holdings (LNTH) Price vs Consensus Price Target

As per the chart shown above, analysts believe that the Lantheus Holdings (LNTH) share price will touch around $91 in next 12-months.

Currently 17 wall-street analysts regularly analyze the financials of Lantheus Holdings on a frequent basis to provide recommendations along with target share price. 17 analysts offering 12-month price forecasts for Lantheus Holdings (LNTH) have a share price target of $91. This median of share price forecast represents a 12.28% upside from the latest price of $81.05 as on 13.03.26.

Lantheus Holdings (LNTH) Share Price Forecast

Home

US Stocks

Lantheus Holdings (LNTH)

Lantheus Holdings Stock Forecast

Lantheus Holdings Stock Forecast & Price Target (Analyst Recommendation) | INDmoney

Percentage Difference

Lantheus Holdings (LNTH): Difference between Current Price & Median Forecasted Price

Below is a chart showing the percentage difference between Lantheus Holdings's share price and its median forecast price. As on 13.03.26, the difference is -28.33%

Lantheus Holdings Forecast and Target Price

Lantheus Holdings (LNTH) Share Price Forecast

Lantheus Holdings (LNTH) Price vs Consensus Price Target

Lantheus Holdings (LNTH) Share Price Forecast v/s Share Price Today

Lantheus Holdings (LNTH): Difference between Current Price & Median Forecasted Price

Lantheus Holdings (LNTH) Share Price Technical Analysis

50 Day Moving Average v/s Current Share Price

200 Day Moving Average v/s Current Share Price